Section Arrow
Quote
SION.NASDAQ
- Sionna Therapeutics Inc
Quotes are at least 15-min delayed:2026/04/23 05:05 EDT
Pre Market
Last
 --
-- (--)
Bid
17.37
Ask
69.12
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 43.2
+1.41 (+3.37%)
Day High 
43.63 
Prev. Close
41.79 
1-M High
46.458 
Volume 
363.49K 
Bid
17.37
Ask
69.12
Day Low
41.72 
Open
41.81 
1-M Low
33.645 
Market Cap 
1.88B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 41.71 
20-SMA 39.79 
50-SMA 37.87 
52-W High 46.458 
52-W Low 10.965 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.88/-2.03
Enterprise Value
1.89B
Balance Sheet
Book Value Per Share
6.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.2224+0.0256+13.01%-- 
Pre Market 0.204 -0.0184 -8.27%
TOVXTheriva Biologics Inc0.3731+0.0344+10.16%0.09PE
Pre Market 0.3398 -0.0333 -8.93%
IOVAIovance Biotherapeutics3.53-0.17-4.59%-- 
Pre Market 3.48 -0.05 -1.42%
REPLReplimune Group2.27+0.41+22.04%-- 
Pre Market 2.23 -0.04 -1.76%
GERNGeron Corp1.55+0.05+3.33%-- 
Pre Market 1.56 +0.01 +0.65%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.